Preclinical in vitro cardiac electrophysiology. A method of predicting arrhythmogenic potential of antihistamines in humans?

Drug Safety

Volumn 21, Issue SUPPL. 1, 1999, Pages 19-31

  Cavero, Icilio ^a   Mestre, Michel ^a   Guillon, Jean Michael ^b   Heuillet, Edith ^a   Roach, Alan G ^a  

^a SANOFI   (France)

^b Centre d'Immunologie Pierre Fabre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CAREBASTINE; CETIRIZINE; EBASTINE; FEXOFENADINE; LORATADINE; MAGNESIUM ION; POTASSIUM ION; TERFENADINE;

ACTION POTENTIAL; ANIMAL CELL; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE FIBER; QT INTERVAL; RABBIT; SIDE EFFECT; SODIUM CURRENT; SUDDEN DEATH; TORSADE DES POINTES;

EID: 0033432746     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921001-00004     Document Type: Conference Paper

References (24)

1. Committee for Proprietary Medicinal Product. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CTMP/986/96: 1997
2. Lindquist M, Edwards RJ. Risks of non-sedating antihistammes. Lancet 1997; 49: 1322
3. Woosley RL. Cardiac action of antihistamines. Ann Rev Toxicol 1996; 36: 233-52
4. Morganroth J, Brown AM, Critz S, et al. Variability of QTc interval: impact on defining drug effect and low frequency cardiac event. Am J Cardiol 1993; 72: 26B-31B
5. Katz AM, Selectivity and toxicity of antiarrhythmic drugs: molecular interactions with ion channels. Am J Med 1998; 104: 179-95
6. Sanguinetti MC, Keating MT. Role of delayed rectifier potassium channels in cardiac repolarization and arrhythmias. News Physiol Sci 1997; 12: 152-7
7. Morganroth J. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definition und mechanisms, Am J Cardiol 1993; 72: 10B-13B
8. Statters DB, Malik M, Ward D, et al. QT dispersion, problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 5: 372-685
9. Ackerman MJ, Clapham DE. Ion channels - basic science and clinical diseases. N Engl J Med 1997; 336: 1575-86
10. Priori SG, Barhanin J, Hauer RNU, et al. Genetic and molecular basis of cardiac arrhythmias. Impact on clinical management. Eur Heart J 1999; 20:174-95
11. Jongsma HJ. Sudden cardiac death. A matter of faulty ion channels. Curr Biol 1998; 8: R568-71
12. Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012
13. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993; 72: 44B-49B
14. Hondeghen I.M, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation 1990; 81: 686-90
15. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98: 2334-51
16. 1. Lettre Pharmacol 1996; 10: 200-7
17. Adamantidis MM, Lacroix DL, Caron JF, et al. Electrophysiological and arrhythmogenic effects of the histamine type-1 receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. J Cardiovasc Pharmacol 1995; 26: 314-27
18. Pusieux FL, Adamantidis MM, Dumotier BM, et al. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377-9
19. Michels M, Van Peer A, Woestenborghs R, et al. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8: 53-62
20. + currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 1998; 124: 663-8
21. Ebastine periodic safety update reports (1st-3rd). Barcelona, Spain: Almirall-Prodesfarma. (Data on file)
22. Thomas M, Maconochic JG, Fletcher E. The dilemma of prolonged QT interval in early drug studies. Br J Pharmacol 1996; 41: 77-81
23. Elming H, Holm E, Jun L, et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998; 19: 1391-400
24. Napolitano C, Schwartz PJ, Cantu F, et al. Identification of a long QT syndrome molecular defect in drug-induced Torsades de Pointes [abstract 1169]. Circulation 1997; 96: 1-211